Cathie Wood, writing on the X platform, stated that according to ARKInvest research, the most far-reaching application of AI will be in healthcare. Deregulation is accelerating this transformation in healthcare. Significant progress has been made in the science of evaluating drug efficacy, with R&D projects collecting evidence across multiple dimensions, including mechanisms of action, biomarker effects, and intermediate endpoints. This confirmatory evidence, ranging from mechanistic data to real-world evidence, can replace a second pivotal trial. Historically, there has been considerable regulatory flexibility in rare diseases and oncology; however, this reduction from two to one is expected to have the greatest impact on common diseases such as cardiovascular and respiratory illnesses, potentially saving up to $350 million per project and shortening development cycles by several years.